Back to mobile site

Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data

February 3, 2017 6:53 AM EST Send to a Friend
BMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login